BridgeBio Pharma Financial Activities - Other 2018-2025 | BBIO
BridgeBio Pharma annual/quarterly financial activities - other history and growth rate from 2018 to 2025. Financial activities - other can be defined as the net amount of items a company reports that are too small to report separately. Additionally, this field holds the sum of items a company reports that cannot be assigned to any other standardized field in the financing activities section of the Cash Flows Statement.
- BridgeBio Pharma financial activities - other for the quarter ending March 31, 2025 was $-0.011B, a 7.15% decline year-over-year.
- BridgeBio Pharma financial activities - other for the twelve months ending March 31, 2025 was $0.441B, a 3913.62% decline year-over-year.
- BridgeBio Pharma annual financial activities - other for 2024 was $0.484B, a 60526.22% decline from 2023.
- BridgeBio Pharma annual financial activities - other for 2023 was $-0.001B, a 195.7% decline from 2022.
- BridgeBio Pharma annual financial activities - other for 2022 was $0.001B, a 100.86% decline from 2021.
BridgeBio Pharma Annual Financial Activities - Other
(Millions of US $) |
| 2024 |
$484 |
| 2023 |
$-1 |
| 2022 |
$1 |
| 2021 |
$-98 |
| 2020 |
$-16 |
| 2019 |
$-54 |
| 2018 |
$14 |
| 2017 |
$3 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Generic Drugs |
$6.426B |
$0.222B |
|
BridgeBio Pharma Inc. discovers, develops and innovates drugs for genetic diseases. The Company's product platform consists of Mendelian, Oncology and Gene therapy. Its product pipeline includes BBP-265, BBP-831, BBP-631 and BBP-454 which are in clinical stage. BridgeBio Pharma Inc. is based in CA, United States.
|
